Cookies are used to help provide a better web service to patients and others.
Uses include: remembering products you add to our cart, understanding what people need and ensuring our website works properly.
Our service contains information about acquiring treatments that have been approved in another country. This includes professional information such as approval details, product information and pricing. By continuing, you are declaring that you are requesting any such information.
Innovative new migraine injection medicine Aimovig (erenumab) is now approved for the European Union by the EMA.
Following a positive opinion on 31 May 2018 by the Committee for Medicinal Products for Human Use (CHMP) the medicine was reviewed by the European Commission, which yesterday finalised the process and approved the medicine. Aimovig (erenumab) has been specifically indicated “...for prophylaxis of migraine in adults who have at least 4 migraine days per month”.
This decision is applicable to all 28 European Union member states and Iceland, Norway and Liechtenstein. Each member state can now start their price discussions with the manufacturer and cost effectiveness assessments. It can take up to 12 months for newly approved medicines in the EU to be made available (which is defined as the first sale) due to these post-approval negotiations. In some European countries it may never be made available.
If you live inside the EU and want to access Aimovig quickly - it is available to order today on our website. For residents outside of the EU, we can help you as well. Our service makes new medicines globally available.
You can read more about Aimovig (erenumab) on the EMA website.